This observation, together with the cell cycle‐dependent expression of CLKs and their role in Aurora B phosphorylation [86, 89], suggests that CLK inhibitors might represent promising therapeutic options for cancers treated with drugs that interfere with mitosis, such as taxanes for triple‐negative breast cancers [97]. Here, CLK1 is linked to cancer.